Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first-line treatment, but details on its design and regulatory approval are still uncertain. Additional studies in lung cancer and CNS cancers will reveal if the drug can succeed beyond this initial result. While the company has enough funding for now, key trials and potential market launch are still years away, making the stock a cautious hold for investors.
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
Remittix announced its final presale price for the RTX token at $0.46, set as the minimum exchange launch price for its market debut on November 24, 2026. Currently, RTX is available at $0.23 during the ongoing presale stage, with the project nearing...
Bitcoin mining can become unprofitable when Bitcoin prices fall or mining difficulty rises, causing some miners to shut down older machines or exit the market. This reduces the total network hashrate, prompting an automatic difficulty adjustment that...
Ether (ETH), the second-largest cryptocurrency by market capitalization, saw its price increase to $2,553 on Binance spot trading as of 12:53 p.m. ET on October 11. This marks a 1.02% rise from one hour earlier when the price was $2,544. The price mo...
Zcash (ZEC) price surged 3.48% within an hour to $1,284 on Binance's spot market, rising from $1,241 just an hour earlier. Over the same period, the token also gained 4.33% compared to its price 24 hours prior. This price movement coincided with sign...
